Skip to main content

Advertisement

SpringerLink
Log in

Clinical Considerations for Insulin Therapy in Older Adults with Type 1 Diabetes

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Type 1 diabetes represents an autoimmune condition with a strong inherited background, and its incidence is increasing worldwide. About 25% of such cases are diagnosed in adulthood, some even as late as the ninth decade of life. The number of older adults with type 1 diabetes is increasing due to improvements in care and decreased mortality rate. However, there is a lack of clinical trials in people older than 70 years of age with type 1 diabetes complicated with comorbidities, frailty, and dependency. The management of type 1 diabetes and the goals of therapy should be individualized based on the patient's health status and life expectancy. In healthier older adults, insulin treatment regimens (multiple daily insulin injections or insulin pump therapy) that approximate the normal physiology of insulin secretion should be used to achieve lower glycemic goals, while reducing the risk of hypoglycemia with frequent glucose monitoring (preferably using continuous glucose monitoring systems). For frail individuals with poor health, simpler insulin regimens and less stringent glycemic targets would be more appropriate. Poor cognition, vision and hearing, impaired mobility, depression, and chronic pain can interfere with complex insulin regimens. In these individuals, the principal goals of therapy are to reduce the acute effects of hyperglycemia, minimize hypoglycemia risk, and optimize quality of life. The newer insulin preparations and technological advances in insulin delivery and blood glucose monitoring have enhanced the management of type 1 diabetes in all age groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. IDF Diabetes Atlas. 2019; 9th edition.

  2. Sinclair AJ, Dunning T, Dhatariya K. Clinical guidelines for type 1 diabetes mellitus with an emphasis on older adults: an executive summary. Diabet Med. 2020;37(1):53–70.

    Article  CAS  PubMed  Google Scholar 

  3. Dhaliwal R, Weinstock RS. Management of type 1 diabetes in older adults. Diabetes Spectr. 2014;27(1):9–20.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Weinger K, Beverly EA, Smaldone A. Diabetes self-care and the older adult. West J Nurs Res. 2014;36(9):1272–98.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Adults O. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S168–79.

    Google Scholar 

  6. LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1520–74.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Classification and diagnosis of diabetes. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-s33.

    Google Scholar 

  8. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37(7):2034–54.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Villareal DT, Banks M, Siener C, Sinacore DR, Klein S. Physical frailty and body composition in obese elderly men and women. Obes Res. 2004;12(6):913–20.

    Article  PubMed  Google Scholar 

  10. Miller SL, Wolfe RR. The danger of weight loss in the elderly. J Nutr Health Aging. 2008;12(7):487–91.

    Article  CAS  PubMed  Google Scholar 

  11. Shapses SA, Riedt CS. Bone, body weight, and weight reduction: what are the concerns? J Nutr. 2006;136(6):1453–6.

    Article  CAS  PubMed  Google Scholar 

  12. Buman MP, Hekler EB, Haskell WL, Pruitt L, Conway TL, Cain KL, et al. Objective light-intensity physical activity associations with rated health in older adults. Am J Epidemiol. 2010;172(10):1155–65.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care. 1988;11(7):567–73.

  14. Zoffmann V, Vistisen D, Due-Christensen M. A cross-sectional study of glycaemic control, complications and psychosocial functioning among 18- to 35-year-old adults with type 1 diabetes. Diabet Med. 2014;31(4):493–9.

    Article  CAS  PubMed  Google Scholar 

  15. Hamann A, Matthaei S, Rosak C, Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2003;26(6):1738–44.

    Article  CAS  PubMed  Google Scholar 

  16. Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28(5):1107–12.

    Article  CAS  PubMed  Google Scholar 

  17. Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g5459.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009;180(4):385–97.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489–97.

    Article  CAS  PubMed  Google Scholar 

  21. Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, et al. Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318(1):33–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Holleman F, van den Brand JJ, Hoven RA, van der Linden JM, van der Tweel I, Hoekstra JB, et al. Comparison of LysB28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care. 1996;19(12):1426–9.

    Article  CAS  PubMed  Google Scholar 

  24. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23(5):583–8.

    Article  CAS  PubMed  Google Scholar 

  25. Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care. 2006;29(8):1812–7.

    Article  CAS  PubMed  Google Scholar 

  26. Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016;2016(6):Cd012161.

    PubMed Central  Google Scholar 

  27. An inhaled insulin (Afrezza). JAMA. 2015;313(21):2176–7.

  28. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47(4):622–9.

    Article  CAS  PubMed  Google Scholar 

  29. Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care. 1993;16(12):1592–7.

    Article  CAS  PubMed  Google Scholar 

  30. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981;4(3):366–76.

    Article  CAS  PubMed  Google Scholar 

  31. Henriksen JE, Vaag A, Hansen IR, Lauritzen M, Djurhuus MS, Beck-Nielsen H. Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as the preferred site. Diabet Med. 1991;8(5):453–7.

    Article  CAS  PubMed  Google Scholar 

  32. Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med. 1980;92(1):59–61.

    Article  CAS  PubMed  Google Scholar 

  33. Henriksen JE, Djurhuus MS, Vaag A, Thye-Rønn P, Knudsen D, Hother-Nielsen O, et al. Impact of injection sites for soluble insulin on glycaemic control in type 1 (insulin-dependent) diabetic patients treated with a multiple insulin injection regimen. Diabetologia. 1993;36(8):752–8.

    Article  CAS  PubMed  Google Scholar 

  34. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia. 1994;37(4):377–80.

    Article  CAS  PubMed  Google Scholar 

  35. Kalra S, Mithal A, Sahay R, John M, Unnikrishnan AG, Saboo B, et al. Indian injection technique study: population characteristics and injection practices. Diabetes Ther. 2017;8(3):637–57.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Messer LH, Berget C, Forlenza GP. A clinical guide to advanced diabetes devices and closed-loop systems using the CARES Paradigm. Diabetes Technol Ther. 2019;21(8):462–9.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Weiss R, Garg SK, Bode BW, Bailey TS, Ahmann AJ, Schultz KA, et al. Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE in-home study. Diabetes Technol Ther. 2015;17(8):542–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, et al. Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG Trial. Diabetes Care. 2018;41(10):2155–61.

    Article  CAS  PubMed  Google Scholar 

  39. Choudhary P, Olsen BS, Conget I, Welsh JB, Vorrink L, Shin JJ. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther. 2016;18(5):288–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501–12.

    Article  CAS  PubMed  Google Scholar 

  41. Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407–8.

    Article  PubMed  Google Scholar 

  42. Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19(3):155–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, Karagiannis T, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ. 2018;361:k1310.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet. 2014;384(9950):1265–72.

    Article  CAS  PubMed  Google Scholar 

  45. Briganti EM, Summers JC, Fitzgerald ZA, Lambers LNJ, Cohen ND. Continuous subcutaneous insulin infusion can be used effectively and safely in older patients with type 1 diabetes: long-term follow-up. Diabetes Technol Ther. 2018;20(11):783–6.

    Article  CAS  PubMed  Google Scholar 

  46. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28(7):1568–73.

    Article  CAS  PubMed  Google Scholar 

  47. Johnson SL, McEwen LN, Newton CA, Martin CL, Raskin P, Halter JB, et al. The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes. J Diabetes Complicat. 2011;25(4):211–5.

    Article  Google Scholar 

  48. Matejko B, Cyganek K, Katra B, Galicka-Latala D, Grzanka M, Malecki MT, et al. Insulin pump therapy is equally effective and safe in elderly and young type 1 diabetes patients. Rev Diabet Stud. 2011;8(2):254–8.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Argento NB, Liu J, Hughes AS, McAuliffe-Fogarty AH. Impact of medicare continuous subcutaneous insulin infusion policies in patients with type 1 diabetes. J Diabetes Sci Technol. 2020;14(2):257–61.

    Article  PubMed  Google Scholar 

  50. Stephens EA, Heffner J. Evaluating older patients with diabetes for insulin pump therapy. Diabetes Technol Ther. 2010;12(Suppl 1):S91–7.

    Article  PubMed  Google Scholar 

  51. Munshi MN, Slyne C, Greenberg JM, Greaves T, Lee A, Carl S, et al. Nonadherence to insulin therapy detected by bluetooth-enabled pen cap is associated with poor glycemic control. Diabetes Care. 2019;42(6):1129–31.

    Article  CAS  PubMed  Google Scholar 

  52. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29(5):682–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Tauschmann M, Hovorka R. Insulin pump therapy in youth with type 1 diabetes: toward closed-loop systems. Expert Opin Drug Deliv. 2014;11(6):943–55.

    Article  CAS  PubMed  Google Scholar 

  54. Vigersky R, Shrivastav M. Role of continuous glucose monitoring for type 2 in diabetes management and research. J Diabetes Complicat. 2017;31(1):280–7.

    Article  Google Scholar 

  55. Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, et al. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(10):2968–79.

    Article  CAS  PubMed  Google Scholar 

  56. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371–8.

    Article  CAS  PubMed  Google Scholar 

  57. Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11(6):1138–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Mattishent K, Loke YK. Detection of asymptomatic drug-induced hypoglycemia using continuous glucose monitoring in older people—systematic review. J Diabetes Complicat. 2018;32(8):805–12.

    Article  CAS  Google Scholar 

  59. Polonsky WH, Peters AL, Hessler D. The impact of real-time continuous glucose monitoring in patients 65 years and older. J Diabetes Sci Technol. 2016;10(4):892–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Litchman ML, Allen NA. Real-time continuous glucose monitoring facilitates feelings of safety in older adults with type 1 diabetes: a qualitative study. J Diabetes Sci Technol. 2017;11(5):988–95.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Argento NB, Nakamura K. Personal real-time continuous glucose monitoring in patients 65 years and older. Endocr Pract. 2014;20(12):1297–302.

    Article  PubMed  Google Scholar 

  62. Toschi E, Munshi MN. Benefits and challenges of diabetes technology use in older adults. Endocrinol Metab Clin N Am. 2020;49(1):57–67.

    Article  Google Scholar 

  63. Pratley RE, Kanapka LG, Rickels MR, Ahmann A, Aleppo G, Beck R, et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020;323(23):2397–406.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Fiallo-Scharer R, Cheng J, Beck RW, Buckingham BA, Chase HP, Kollman C, et al. Factors predictive of severe hypoglycemia in type 1 diabetes: analysis from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized control trial dataset. Diabetes Care. 2011;34(3):586–90.

    Article  PubMed  Google Scholar 

  65. Laiteerapong N, Karter AJ, Liu JY, Moffet HH, Sudore R, Schillinger D, et al. Correlates of quality of life in older adults with diabetes: the diabetes & aging study. Diabetes Care. 2011;34(8):1749–53.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Lee PG, Cigolle C, Blaum C. The co-occurrence of chronic diseases and geriatric syndromes: the health and retirement study. J Am Geriatr Soc. 2009;57(3):511–6.

    Article  PubMed  Google Scholar 

  67. Valencia WM, Botros D, Vera-Nunez M, Dang S. Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine. Curr Diab Rep. 2018;18(10):95.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Medicine, University of Florida College of Medicine-Jacksonville, 653-1 West 8th Street, 4th Floor-LRC, Jacksonville, FL, 32209, USA

    Gunjan Y. Gandhi & Arshag D. Mooradian

Authors
  1. Gunjan Y. Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arshag D. Mooradian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arshag D. Mooradian.

Ethics declarations

Funding

No sources of funding were used to conduct this review or prepare this manuscript. No writing assistance was utilized in the production of this manuscript.

Conflict of interest

The authors have no conflicts of interest that are directly relevant to the content of this article.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Author contributions

GYG: Review of literature, interpretation of data, preparation of the manuscript, and critical revision for intellectual content. ADM: Article concept and design, interpretation of data, and critical revision of the manuscript for intellectual content.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gandhi, G.Y., Mooradian, A.D. Clinical Considerations for Insulin Therapy in Older Adults with Type 1 Diabetes. Drugs Aging 39, 23–37 (2022). https://doi.org/10.1007/s40266-021-00900-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-021-00900-3

Search

Navigation